CRISPR-Cas-Based Gene Therapy to Target Viral Infections

Research output: Chapter in Book/Report/Conference proceedingChapterAcademicpeer-review

Abstract

In recent years, there is an increasing demand for the development of new antiviral strategies due to the prevalence of viral infections such as those caused by the human immunodeficiency (HIV) or the hepatitis B and C viruses (HBV and HCV) and the emergence of a variety of “new” viruses including SARS-CoV-2. The pharmaceutical industry and the scientific community work on the development of new antiviral drugs, including the repurposing of previously approved drugs. But alternative strategies such as the development of novel RNA-based therapeutics based on the clustered regularly interspaced short palindromic repeats (CRISPR)- Cas system are also welcome. Here we discuss different aspects of the use of CRISPR-Cas technology in the broad field of virology, ranging from applications in the diagnosis of viral infections to the development of novel antiviral treatments. After a brief introduction on the CRISPR-Cas technology, we will explore the advantages and limitations of this antiviral approach and discuss the future prospects for improvement of diagnostics and therapeutics and their potential for future clinical application.
Original languageEnglish
Title of host publicationBiotechnologies for Gene Therapy: RNA, CRISPR, Nanobots, and Preclinical Applications
PublisherSpringer International Publishing
Pages85-125
ISBN (Electronic)9783030933333
ISBN (Print)9783030933326
DOIs
Publication statusPublished - 1 Jan 2022

Publication series

NameBiotechnologies for Gene Therapy: RNA, CRISPR, Nanobots, and Preclinical Applications

Cite this